Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

doi:10.3390/ijms12107163

This article is

freely available
re-usable

Int. J. Mol. Sci. 2011, 12(10), 7163-7185; doi:10.3390/ijms12107163

Review

Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

In-Sung Song, Hyoung-Kyu Kim, Seung-Hun Jeong, Sung-Ryul Lee, Nari Kim, Byoung Doo Rhee, Kyung Soo Ko and Jin Han*

National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan, 614-735, Korea

* Author to whom correspondence should be addressed.

Received: 29 July 2011; in revised form: 30 September 2011 / Accepted: 20 October 2011 / Published: 21 October 2011

(This article belongs to the Special Issue Oxidative Stress and Mitochondria)

Download PDF Full-Text [544 KB, uploaded 21 October 2011 13:52 CEST]

Abstract: Mitochondria are involved either directly or indirectly in oncogenesis and the alteration of metabolism in cancer cells. Cancer cells contain large numbers of abnormal mitochondria and produce large amounts of reactive oxygen species (ROS). Oxidative stress is caused by an imbalance between the production of ROS and the antioxidant capacity of the cell. Several cancer therapies, such as chemotherapeutic drugs and radiation, disrupt mitochondrial homeostasis and release cytochrome c, leading to apoptosome formation, which activates the intrinsic pathway. This is modulated by the extent of mitochondrial oxidative stress. The peroxiredoxin (Prx) system is a cellular defense system against oxidative stress, and mitochondria in cancer cells are known to contain high levels of Prx III. Here, we review accumulating evidence suggesting that mitochondrial oxidative stress is involved in cancer, and discuss the role of the mitochondrial Prx III antioxidant system as a potential target for cancer therapy. We hope that this review will provide the basis for new strategic approaches in the development of effective cancer treatments.

Keywords: ROS; mitochondria; peroxiredoxin III; cancer; antioxidant; oxidative stress; therapy

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Song, I.-S.; Kim, H.-K.; Jeong, S.-H.; Lee, S.-R.; Kim, N.; Rhee, B.D.; Ko, K.S.; Han, J. Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy. Int. J. Mol. Sci. 2011, 12, 7163-7185.

AMA Style

Song I-S, Kim H-K, Jeong S-H, Lee S-R, Kim N, Rhee BD, Ko KS, Han J. Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy. International Journal of Molecular Sciences. 2011; 12(10):7163-7185.

Chicago/Turabian Style

Song, In-Sung; Kim, Hyoung-Kyu; Jeong, Seung-Hun; Lee, Sung-Ryul; Kim, Nari; Rhee, Byoung Doo; Ko, Kyung Soo; Han, Jin. 2011. "Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy." Int. J. Mol. Sci. 12, no. 10: 7163-7185.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert